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 ABSTRACT 
Background: The purpose of this study was to determine fragile histidine triad (FHIT) and 
p53 protein expression, and to analyze FHIT and p53 gene status in keratocystic odontogenic 
tumor (KOT), dentigerous (DC) and radicular cysts (RC).  
Methods: The methods used were immunohistochemistry and molecular genetic methods 
including loss of heterozigosity (LOH) and gene sequencing.  
Results: FHIT protein expression was different among groups. Aberrant expression was the 
highest in KOT, then RC and DC. p53 protein expression was different among groups. Loss 
of heterozygosity (LOH) in paraffin embedded specimens was detected in 22.6% and 12.9% 
for FHIT and p53, respectively. Mutation of p53 gene at codon 237 was observed in only two 
specimens (1 KOT, 1 DC).  
Of the six frozen specimens, three exhibited FHIT gene LOH (2 RC, 1 KOT). KOT showed 
loss of exons 6-7 at FHIT locus and mutation at codon 237 at p53 locus, but this could be a 
chance result. 
Conclusion: Aberrations of FHIT and p53 genes/proteins could be considered markers 
responsible for the development of odontogenic lesions.  
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Fragile histidine triad (FHIT) is a tumor-suppressor gene isolated and identified by 
collaborating researchers in the USA and Japan in 1996 and it was shown to span the most 
common human fragile chromosomal site FRA 3B at 3p14.2.1,2  Besides 3p14.2, there are 3 
other major regions at 3p shown to be involved in allelic losses in human malignancies: 3p25, 
3p21.3 and 3p12.3,4 The region 3p14.2 contains FRA3B,1,5 familial kidney cancer-associated 
translocation breakpoint t(3;8)(p14.2;q24),6 and papilloma virus integration sites.7 Studies on 
FHIT gene demonstrated that its expression is altered in many human epithelial cancer cell 
lines including lung, bladder, breast, cervical carcinomas, and that it is frequently a target of 
homozygous deletions at 3p14.2.2, 8, 9 Role of the FHIT gene has been studied in primary 
cancers of the oral cavity, tongue, oral squamous cell carcinoma and head and neck squamous 
cell carcinoma.10-12 FHIT functions as a tumor suppressor in vivo and in vitro and its over 
expression induces apoptosis.10 
FHIT gene encodes a 147 amino acid protein showing 69% similarity in a core region of 109 
amino acids to diadenosine5',5'''P1, P4-tetraphosphate (Ap4A) hydrolase from the fission yeast 
Schizosaccaromyces pombe, a member of histidine triad protein family.1 Aberration of FHIT 
gene is estimated on the level of DNA loss of heterozigosity analysis (LOH), altered mRNA 
FHIT transcripts and absence or reduction of the FHIT protein.13-15  
Fragile histidine triad mRNA alterations are also detected in normal tissues and the 
abnormality can be due to abnormal splicing and processing of the transcripts, since the gene 
is located in a region prone to stress-induced damage and some of the genetic changes 
observed, might be a reflection of an intrinsic instability due to cancer cell growth.16,17 
The p53 gene is one of the most common tumor-suppressor genes located on the short arm of 
chromosome 17. It spans a region of 20 kb and is made of 11 exons which encode nuclear 
phosphoprotein having molecular weight of 53 kDa.18  The disturbed function of p53 results 
in uncontrolled proliferation of the cell. The mutations of p53 are present in more than 50% of 
malignant tumors and are commonly related to early and frequent death, decreased 
differentiation of cells and early recurrence.19-21 In normal tissue p53 protein has a short half-
life and cannot be detected using immunohistochemical techniques, whereas the p53 gene 
mutation produces increased stability and over expression of p53 protein.22 
Keratocystic odontogenic tumor (formerly odontogenic keratocyst) and odontogenic cysts are 
derived from the remnants of odontogenic epithelial cells. It has been postulated that there is a 
regulated balance between cell proliferation, differentiation and death in the development of 
the jaw cysts resulting in the specific histopathology in the lining epithelium.23 This suggests 
that different factors may be involved in the development of these lesions, and numerous 
papers have dealt with the expression of tumor-suppressor genes and oncogens in KOT, DC 
and RC. 23-31 The higher incidence of p53 aberration in former OKC then in DC and RC was 
reported.23,24,27 According to the available literature no studies on FHIT in KOT and 
odontogenic cysts were performed.  
The purpose of this study was to determine differential expression of FHIT as an apoptosis 
related factor and p53 as a marker for, both cellular proliferation and apoptosis. 
Immunohistochemical and molecular methods were used to clarify details of the epithelial 
lining cells’ proliferation and death, particularly with respect to aggressive clinical behavior 
of former OKCs, in the context of new WHO classification according to which the former 
OKCs have been classified as benign neoplasm- KOT.28   
 
MATERIALS AND METHODS 
 
Tissue specimens 
Ninety two paraffin embedded specimens of odontogenic lesions were obtained from 
Department of Pathology, School of Medicine, University of Zagreb, Croatia, Institut für 
pathologie, Universität Hamburg, Germany and Abteilung für Chirurgie Klinik für Zahn-, 
Mund-, Kieferheilkunde, Universität Würzburg, Germany. Of the 92 specimens, 38 were 
KOT, 13 dentigerous cysts (DC) and 41 radicular cysts (RC). The paraffin embedded 
specimens were collected and evaluated in concordance with all ethical and legal 
requirements. 
Six specimens of odontogenic cysts and blood samples were obtained from Department of 
Oral Surgery, Clinical Hospital Dubrava, Zagreb, Croatia. The specimens of odontogenic 
cysts were obtained during routine surgery and were snap frozen in liquid nitrogen shortly 
after surgical removal and stored at -80°C. A part of each tissue sample was embedded in 
paraffin. Sections of each paraffin block were stained with hematoxylin and eosin to confirm 
the tissue analyzed. Of the 6 samples 1 was KOT, 1 DC and 4 RC. Full blood samples in acid 
citrate dextrose tubes were obtained from the patients after the surgery by trained personnel. 
The patients signed informed consent for participating in the research before the surgery.  
 
Immunohistochemical examination of FHIT and p53 proteins 
Four μm sections of 92 paraffin embedded samples were cut and mounted on slides for 
immunohistochemical analysis of FHIT protein (48 male and 44 female, age ranged from 14 
to 69, mean age 40.9; 38 KOT, 13 DC, 41 RC). They were further deparaffinized and 
rehydrated through xylene and graded alcohols, and incubated in 3% H2O2 in methanol for 10 
minutes to block endogenous peroxidase activity. Antigen retrieval was then performed by 
heating slides in microwave oven immersed in citrate buffer (750 W, pH 6, 15 minutes). 
Nonspecific antibody binding was blocked with pig serum diluted by PBS (1:20, 20 minutes). 
Anti-FHIT rabbit policlonal primary antibody (Zymed Laboratoires Inc., San Francisco, USA) 
was diluted by PBS (1:80). Sections were incubated for 12 hours at 4°C with antibody in PBS 
containing 5% rabbit serum. The sections were processed for detection of the positive 
immunohistochemical reaction using Universal LSAB+ kit (DAKO Corp., USA) 
(Biotinylated link and Streptavidin-HRP) and Liquid DAB (DAKO Corp., USA). For the 
negative control, the primary antibody was replaced with normal rabbit serum. Tumor tissue 
with the wild-type of FHIT gene (breast carcinoma) was used as positive control.  
Immunohistochemical evaluation of p53 protein was performed on 64 samples (32 KOT, 13 
DC, 19 RC) as described previously.27 The samples of KOT and RC for p53 protein 
expression analysis were chosen according to the results of their, negative or weakly positive, 
reactivity to FHIT. Certain samples were not analyzed for p53, regardless of their positive or 
weakly positive reaction to FHIT, because the paraffin embedded sample was initially too 
small and we could not obtain good sections for p53 analysis. Total number of DC samples 
was only 13, so all DC samples were analyzed for p53 reactivity regardless of their FHIT 
reactivity.  
The intensity of staining was evaluated for the epithelial cells of the cyst lining as negative, 
weak positive or strong-positive staining, for FHIT and p53 protein. The criteria were as 
follows: no staining detected in epithelial cells was classified as negative reaction, staining 
detected in <25% epithelial cells was classified as week positive reaction and if more than 
25% epithelial cells showed staining the reaction was classified as strong-positive reaction. 
The percentage of FHIT-stained cytoplasm or p53-stained nuclei was calculated manually 
from a minimum of 1000 nuclei i.e. cells at a magnification of 400x. The staining was 
regarded as positive regardless of the staining intensity. Cells within the cyst wall (fibrocites 
and lymphocites in the case of RC) served as the internal negative control. The specimens 
were histologicaly evaluated by a trained pathologist.  
 
Isolation of DNA and RNA and reverse transcription 
After deparaffinisation,32 genomic DNA from microdissected epithelial cyst lining was 
extracted from the tissue collected in 500 μl microcentrifuge with digestion buffer (0.9% 
Tween20, 0.9% Trion X-100, 5 nM EDTA, 2mM DTT, 10 mM TrisHCl, pH 7.5) and 
Proteinase K (20μg/ml; Roche Diagnostics, Mannheim, Germany). Nucleic acids were 
quantified by reading UV absorbance at 260 nm. The extracts were stored at -20° until 
assayed. Control normal DNA of the patients was extracted from corresponding normal tissue 
surrounding the lesion.  
Genomic DNA from micro dissected epithelial lining of frozen samples was extracted as 
described, but without deparaffinisation.30 Control normal DNA from the whole blood 
samples was isolated using a standard phenol-extraction procedure.33 
Total RNA from snap frozen tissue specimens was extracted using RNAzolTMB reagent 
(Biogenesis, Poole, UK) according to manufacturer's protocol. Recovered RNA was assayed 
by a 260/280 nm ratio. The reaction volume of 20 μl for reverse transcription contained 5 μg 
denaturated RNA (10 min, 70 °C), 2 μl  10 x reverse transcriptase buffer (500 Mm Tris HCl, 
pH 8.3, 300 mM KCl, 80 mM MgCl2, 100 mM dithiothreitol; New England BioLabs Inc.), 
2μl 10 mM each dNTPs (Roche), 25 U Moloney Murine Leukemia Virus reverse transcriptase 
(New England BioLabs Inc., Frankfurt am Main, Germany) and 0.4 mM oligo (dT)18 (New 
England BioLabs Inc.). The reaction was performed at 42°C for 1 hour.  The reaction was 
inactivated at 70˚C for 15 min and at 94˚C for 3 min. The cDNA was used as a template in the 
following PCR reactions. 
 
PCR amplification, FHIT and p53 gene expression analysis 
The FHIT gene expression analysis was performed by nested RT-PCR method as described 
previously.34 Half of microliter of cDNA was used for PCR amplifications with primers 5U2 
and 3D2 from FHIT exons 1 and 10, respectively. Two microliters of first PCR products were 
used for nested PCR amplifications with primers 5U1 and 3D1 from FHIT exons 3 and 10, 
respectively. The PCR products were resolved by agarose gel electrophoresis (1.5% agarose 
stained with 0.5 μg/ml ethidium bromide). The sequencing of aberrant PCR products was 
performed as described previously.35 
The p53 gene expression analysis was performed as described by Li et al.29 Forty cycles were 
performed (94°C, 55 °C, 72°C, 1 min each) to amplify exons 5-9 of p53 gene in a 100 μl 
reaction mixture. The sufficient PCR target products for the exons 5-9 were obtained only 
with DNA templates obtained from some paraffin sections and all fresh frozen samples. The 
PCR products were resolved by agarose gel electrophoresis. p53 gene mutations analysis was 
performed by SSCP analysis of all p53 gene exons. Mutations were detected by direct 
sequencing of the relevant genomic DNA fragments with aberrant profile in SSCP analysis 
using CircumVent TM Thermal Cycle dideoxy DNA sequencing kit (New England Biolabs) 
according to the manufacturer's instructions. Mutations were additionally confirmed using 
fluorescence-based dideoxy sequencing on Applied Biosystems Model 373A automated 
sequencer (ABI Foster City, Ca, USA). 
 
Loss of heterozigosity analysis (LOH) 
Thirty one paraffin embedded samples (11 KOT, 10 DC, 10 RC) were chosen for LOH 
analysis of FHIT and p53 loci according to their aberrant immunohistochemical reaction for 
either FHIT, p53 or both. All six frozen samples (1 KOT, 1 DC, 4 RC) were analyzed for 
FHIT and p53 LOH. Five μm sections of paraffin embedded samples were cut for 
microdissection and DNA extraction from the epithelial lining of the cyst samples. 
Constitutional DNA was obtained from the blood samples corresponding to the frozen cyst 
specimens.  
To analyze LOH at the FHIT gene, D3S1300 dinucleotide repeat and D3S4103 trinucleotide 
repeat were used as described previously 34.  
LOH at the p53 gene locus was analyzed by VNTR analysis and highly informative exogenic 
(CA)n repeat as it was previously described.36 
LOH was recognized as visible change in alleles in terms of allele ratio in cyst epithelial 
lining compared with matching normal tissue.     
Statistical analysis 
The data of FHIT and p53 protein expression, and LOH analysis for FHIT and p53 gene in 
KOT, DC and RC, were compared with modified Fisher’s exact test as described in SAS 
Procedures Guide.37 The proportion of FHIT and p53 aberrant expression was compared to 
the number of epithelial cell layers using Chi-square test. The SAS System for Windows, 
Release 8.02, TS Level 02M0 (SAS Institute Inc., Cary, NC, USA) was used. 
 
RESULTS 
 
FHIT and p53 protein expression in paraffin embedded samples 
To investigate the reactivity of FHIT protein, we examined 38 KOT, 13 DC and 41 RC 
samples embedded in paraffin. Reactivity to FHIT was for KOT: (-) 28, (+) 9, (++) 1; for DC: 
(-) 4, (+) 2, (++) 7; for RC: (-) 20, (+) 12, (++) 9.   The intensity of aberrant (negative) 
immunohistochemical reaction for FHIT protein was different between the three groups 
(p=0.00078), and it was the highest in KOT, then RC and DC. Although the reaction for FHIT 
was negative in the majority of specimens, in the cases where the reaction was positive it was 
observed in the cytoplasm of the epithelial lining (Fig 1). In KOT, staining was observed 
mostly in suprabasal cells and in DC and RC in basal to superficial epithelial cells.  
The intensity of p53 immunostaining was weak, and it was the highest in KOT, but statistical 
analysis showed no difference in intensity between KOT, DC and RC (p=0.9344). The 
staining in KOT was mostly observed in suprabasal cells, and in DC and RC in basal to 
superficial epithelial cells of the nuclei of epithelial cells (Figure 2). The results of 
immunohistochemical expression of FHIT and p53 proteins are shown in Table 1.  
The aberrant expression of FHIT and p53 proteins was compared to the number of epithelial 
cell layers. All 92 samples in the case of FHIT and 64 in the case of p53 were divided in two 
groups with the cyst specimens with  5 layers and >5 layers. The samples showing weakly 
positive (+) and strong positive (++) reaction were pooled. Using chi-square test (p<0.05) it 
was determined that the specimens with more than 5 epithelial cell layers gave aberrant 
(negative) reaction to FHIT in significantly more cases (χ2=4.19). In the case of p53 protein, 
specimens with >5 epithelial cell layers gave positive (+ and ++) reaction in significantly 
more cases (χ2=8.43).  
 
Loss of heterozigosity analysis (LOH) 
Thirty one paraffin embedded samples were chosen for LOH analysis of FHIT and p53 loci 
according to their aberrant immunohistochemical reaction for either FHIT, p53 or both (11 
KOT, 10 DC and 10 RC). 75% of the samples were informative for both markers of FHIT 
locus and 49 % of were informative for p53 locus. Mutation of FHIT other than LOH, was not 
observed in neither of the specimens, while the mutation at codon 237 of p53 was observed in 
2 samples (1 KOT and 1 DC). Normal tissues did not show loss of heterozigosity at the gene 
loci examined. Loss of heterozygosity of FHIT gene was detected in 22.6% of the samples 
examined (45% in KOT, 10% in RC, and 10% in DC). Loss of heterozygosity of p53 gene 
was detected in 12.9% of the samples (27.3% in KOT, 10% in DC and 0% in RC). Protein 
expression of the two genes was correlated with the results of DNA analysis, and it was 
noticed that the p53 gene mutation was found in 2 of 11 examined cases of KOT which 
exhibited normal p53 protein expression. p53 mutation was not found in RC although it 
would be expected differently based on immunohistochemical analysis which showed strong 
positive immunohistochemical reaction to p53 in 26% of RC. The results of LOH and other 
mutation analysis of FHIT and p53 genes in paraffin embedded samples are shown in Table 2. 
FHIT and p53 gene analysis in frozen samples  
The frozen samples were analyzed for FHIT and p53 LOH and other mutations.  The results 
of DNA analysis at FHIT and p53 loci in frozen odontogenic cyst samples are shown in Table 
3 and Figure 3 and 4. Since there were only six frozen specimens no consistent conclusions 
can be drawn from the obtained data.  
 
DISCUSSION 
 
Odontogenic tumors and allied lesions have been extensively studied in the past decade and 
new findings lead to new and improved classification of the lesions. 28,38 Recent findings 
concerning the events taking place at the molecular level, together with the clinical behavior 
of the lesions, gave the better insight into the nature of the lesions. The most recent WHO 
classification of head and neck tumors referred to the former OKC as keratocystic 
odontogenic tumor (KOT), a benign odontogenic tumour arising from odontogenic epithelium 
with mature fibrous stroma without odontogenic ectomesenhyme. 28  
Radicular cysts are epithelial lesions which arise from the epithelial residues (rest of 
Malassez) in the periodontal ligament as a consequence of inflammation which follows the 
death of a dental pulp. The dentigerous cyst is the second most-frequent cystic lesion of the 
jaws which usually encloses the crown of un unerrupted tooth. 28 
A new classification gives enlarged terminology and diagnostic framework, but there are still 
many uncertainties concerning molecular and cellular mechanisms underlying the 
development and behavior of tumors arising from epithelium of the odontogenic apparatus 
and allied lesions, which gives the inspiration for further research into the lesions. 23,26,39,40 
Altered expression of oncoproteins and tumor-suppressor proteins in odontogenic cysts, and 
the mutations of genes regulating the cell cycle have been reported for different odontogenic 
cysts. 23,25- 27,29 Furthermore, functional genomic analyses of malignancies related to jaws, 
support the hypotheses that they can arise from odontogenic cysts, apart from arising de novo 
or secondary to a tumor.41-43 Furthermore, there are reports on transformation of former OKC 
into squamous cell carcinoma and DC into ameloblastoma.44,45 
In our study we demonstrated variable expression of FHIT tumor suppressor protein in 
paraffin embedded samples of odontogenic lesions. Negative immunohistochemical reaction 
was the highest in KOT (74%) than in RC (49%) and DC (31%).  Pavelic 34 reported that 
FHIT gene is disrupted in head and neck squamous cell carcinomas (HNSCC) and lung 
cancer, and suggested a strong correlation between the loss of FHIT protein function and 
increased tumor cell proliferation and low rate of apoptosis. Former OKCs recur at greater 
frequency and their epithelial lining has greater proliferative potential than that of other types 
of odontogenic cysts. 26,27,29  Our results, showing the highest negative reaction to FHIT in 
KOT, suggest that the disruption of FHIT may induce cell proliferation.   
Loss of heterozygosity of FHIT gene was detected in 45% of informative cases of KOT, 10% 
of DC, and 10% of RC.  In frozen specimens, FHIT gene LOH was observed in three, out of 
six, specimens (2 RC, 1 KOT). Loss of exons 6-7 of the FHIT gene was found in KOT 
specimen. Loss of FHIT protein function and higher incidence of FHIT mutation in benign 
neoplasm KOT, may be important in its development and/or progression.  
Given that defective FHIT genes were found in DC and RC, the inactivation of FHIT gene is 
likely to be an early event in the pathogenesis of odontogenic cysts. Our data suggest strong 
difference in the FHIT aberration between KOT and DC and RC. Less aggressive DC and RC 
have much less incidence of FHIT loss in comparison to KOT. It was reported that the FHIT 
gene could be aberrant in non-neoplastic or premalignant tissues, although the changes 
increased with progression of lesions from normal tissue and dysplasia to carcinoma in situ 
and cancer. 9, 10, 17, 33 Tanimoto10 examined abnormalities of FHIT genes in HNSCC and 
preamlignant lesions: leukoplakias and erythroplakias, and found abnormal FHIT transcripts 
in HNSCC samples and in two of seven premalignant lesions. One patient with premalignant 
lesion with abnormal FHIT transcript developed oral SCC during a 3-year follow up period. 
Tokuchi 17 found significant difference in the frequency of abnormal FHIT transcripts 
between lung cancer and paired normal lung, while the difference in the frequency of 
abnormal transcripts was not significant between lung cancer and normal control lung. 
Therefore, the authors suggested that the presence of abnormal FHIT transcripts is not cancer 
specific in the case of lung cancer, and the abnormality may be due to abnormal splicing and 
processing of the transcripts since the gene is located in a region prone to stress-induced 
damage.17      
Furthermore, some studies reported that some mutagenic compounds such as benzo()piren 
diol-epoxide, which is a major constituent of tobacco smoke, induce molecular alterations of 
FHIT and p53 gene in human lung cancer.34  Both p53 and FHIT tumor suppressor gene 
mutations have been frequently found in other types of carcinomas. 2, 11, 15, 35, 46 According to 
the available literature FHIT gene has not been studied in odontogenic cysts and KOT. 
The frequency of positive immunohistochemical reaction for p53 protein in paraffin 
embedded specimens of KOT, DC and RC was 29%, 15% and 26%, respectively, and there 
was no difference between the three groups (p=0.9344). The intensity of p53 immunostaining 
was weak, and in KOT it was mostly observed in suprabasal cells, and in DC and RC in basal 
to superficial epithelial cells which is in concordance with previous reports. 23,27,29   Loss of 
heterozygosity of p53 gene was detected in 27.3% of informative cases of KOT and 10% of 
DC, while it was not observed in RC. The mutation of p53 gene at codon 237 was observed in 
2 paraffin embedded specimens (1 KOT and 1 DC). In snap frozen specimens, p53 mutation 
at codon 237 was found in KOT.   
Our results as well as those of other authors show that p53 mutations are more frequently 
present in KOT i.e. former OKC, compared with other types of cysts.21, 23,27,29 However, we 
did not find any mutation in RC. These results support the assumption that the inactivation of 
p53 may confer odontogenic lesions with local growth and aggressive properties attributed to 
KOT. Agaram 24 also reported that a significant number of former OKC show clonal LOH of 
p53, along with LOH of some other common tumor-suppressor genes. Furthermore, the 
inactivation of p53 could even be one event in the multi-step genetic process leading to the 
malignant transformation of KOT and DC reported in the literature.41,44,45  
Immunohistochemical analysis showed that the samples with more than 5 epithelial cell layers 
gave positive reaction to p53 in significantly more cases (p<0.05) which confers the lesions 
with increased cell division and local growth. This is in concordance with Regezi 47 report 
where the mitotic index in OKC was similar to that in ameloblastoma.  
In conclusion, our results support the hypothesis that FHIT gene alteration is involved in 
development of KOT and odontogenic cysts, and that aberrant FHIT and p53 genes could be 
markers of local invasiveness or even neoplastic nature. Aberrant FHIT gene may be early 
event in odontogenic cyst development.  
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Table 1 
  
FHIT 
N=92    
 p53  
N=64  
Cyst type      -     +     ++ Cyst type    -    +     ++ 
KOT        
(38cases) 
28 
(74%) 
9  
(24%) 
1    
(2%) 
KOT        
(32 cases) 
16 
(50%) 
7  
(22%) 
9  
(29%) 
DC           
(13cases) 
4  
(31%) 
2  
(15%) 
7    
(54%) 
DC           
(13 cases) 
8  
(62%) 
3  
(23%) 
2  
(15%) 
RC           
(41cases) 
20 
(49%) 
12 
(29%) 
9   
(22%) 
RC           
(19cases) 
9  
(48%) 
5  
(26%) 
5  
(26%) 
 
- negative reaction (0% of the cells showing reactivity); + positive reaction (<25% of the cells showing 
reactivity); ++ positive reaction (>25% of the cells showing reactivity); KOT- keratocystic odontogenic tumor; 
DC- dentigerous cyst; RC- radicular cyst 
 
 
 
 
Table 2 
 
N=31 FHIT LOH p53 LOH OTHER MUTATIONS 
KOT 
(11cases) (5 cases) 45% (3 cases) 27.3% (1 case) p53 at codon 237 
DC   
(10 cases) (1 case) 10% (1 case)10% (1 case) p53 at codon 237 
RC  
(10 cases) (1 case) 10% (0 cases) 0%  - 
 
LOH- loss of heterozigosity; KOT- odontogenic keratocyst; DC- dentigerous cyst; RC- radicular cyst;  
 
 
 
 
Table 3 
 N=6 FHIT LOH P53 LOH OTHER MUTATIONS 
KOT (1 case) YES - P53 at codon 237 FHIT: loss of exons 6-7 
DC (1 case) - - - 
RC (4 cases) 2 cases - - 
 
LOH- loss of heterozigosity; YES- LOH found in odontogenic cyst sample; KOT- odontogenic keratocyst; DC- 
dentigerous cyst; RC- radicular cyst;  
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